New Delhi, July 31 -- Tata Capital will invest Rs 225 crore or $30 million for 0.85% stake in Biocon's biosimilar business Biocon Biologics. The deal values it at an equity valuation of Rs 26,250 crore (about $3.5 billion) and an enterprise valuation of Rs 30,400 crore ($4 billion), the Biotech said on Friday. Further, the transaction is subject to standard condition precedents and approvals. Thus, post the completion of this transaction, the biotech giant will hold a 95.25% stake in Biocon Biologics.

Talking about the deal, Dr Christiane Hamacher, CEO, Biocon Biologics, said in a statement:

"We appreciate the conviction of our institutional investors in the 'value creation' story of Biocon Biologics as a fully integrated 'pure-play' gl...